Salute e Benessere
IRBM Expands Functional Genomics Platform to Strengthen Early Drug Discovery
To further enhance target validation, IRBM is expanding its genome editing toolkit with CRISPR tiling to systematically map functional domains within coding and regulatory regions, along with base and prime editing to introduce precise nucleotide modifications. These next-generation approaches—combined with the platform's high-throughput CRISPR screening, including stem cell engineering—are instrumental in building robust disease models and improving the reliability of target validation.
said Sara Tomaselli , PhD, Head of Functional Genomics at IRBM.
The platform's screening capabilities include genome-wide and targeted CRISPR libraries for knockout (CRISPR KO), inhibition (CRISPRi), and activation (CRISPRa), enabling in-depth exploration of gene function and associated pathways. In parallel, IRBM's cell engineering expertise—spanning patient-relevant models and iPSC-derived systems—supports disease modeling across oncology, neurodegeneration, and rare disorders. Multi-omics integration, including high-content imaging, single-cell transcriptomics, and proteomics, provides deeper functional characterization of drug targets.
IRBM's Functional Genomics Platform is part of a broader, fully integrated drug discovery ecosystem, ensuring that genetic insights translate into meaningful preclinical models and drug development strategies. By combining functional genomics with expertise in medicinal chemistry, biomarker discovery, and preclinical pharmacology, IRBM enables biopharma innovators to approach target validation with greater confidence.
said Carlo Toniatti , MD, PhD, Chief Scientific Officer at IRBM.
IRBM's collaborative approach allows biotech startups, pharmaceutical companies, and venture-backed teams to access functional genomics expertise without the need for in-house infrastructure. With customized solutions spanning genetic screening, engineered cell models, and mechanistic studies, IRBM provides practical, scientifically rigorous support at key points in drug discovery.
To learn more about IRBM's Functional Genomics Platform and collaboration opportunities, visit www.irbm.com.
IRBM is a contract research organization (CRO) focused on early-stage drug discovery. With a track record of delivering preclinical candidates across oncology, neurodegeneration, and infectious diseases, IRBM partners with biotech and pharmaceutical innovators to advance therapeutic development with scientific precision and transparency.
Photo - https://mma.prnewswire.com/media/2656624/IRBM_Functional_Genomics_Platform.jpg
Logo - https://mma.prnewswire.com/media/2656507/IRBM_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/irbm-expands-functional-genomics-platform-to-strengthen-early-drug-discovery-302418746.html